Thomas J Weber MD
Osteoporosis & Bone Metabolism Medicine, Parathyroid
Professor of Medicine, Duke University
Join to View Full Profile
40 Duke Medicine CirDurham, NC 27710
Phone+1 919-668-1367
Fax+1 919-668-1366
Dr. Weber is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 1993 - 1997
Yale-New Haven Medical CenterResidency, Internal Medicine, 1989 - 1992
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1989
Certifications & Licensure
NC State Medical License 1994 - 2025
PA State Medical License 2002 - 2002
CT State Medical License 1992 - 1993
OH State Medical License 1990 - 1992
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Publications & Presentations
PubMed
- 10 citationsLong-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia.Thomas J Weber, Erik A Imel, Thomas O Carpenter, Munro Peacock, Anthony A Portale
The Journal of Clinical Endocrinology and Metabolism. 2022-12-17 - 7 citationsEfficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study.Maria Luisa Brandi, Suzanne Jan de Beur, Karine Briot, Thomas Carpenter, Hae Il Cheong
Calcified Tissue International. 2022-10-01 - 29 citationsDiagnosis and Management of Tumor-induced Osteomalacia: Perspectives From Clinical Experience.Kathryn Dahir, María Belén Zanchetta, Irinel Stanciu, Cemre Robinson, Janet Y. Lee
Journal of the Endocrine Society. 2021-09-01
Journal Articles
- A Randomized, Double‐Blind, Placebo‐Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti‐FGF23 Antibody, in Adults with X‐Linked Hypophosphatemia: W...Thomas Weber, Mary D Ruppe, Anthony A Portale, Erik A Imel, Thomas O Carpenter, Karl L Insogna, Farzana Perwad, Pisit Pitukcheewanont, Journal of Bone and Mineral Research
Press Mentions
Osteoporosis Screening Guidelines Updated: Do You Need a Bone Scan?January 15th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
